Science News About Clinical Research and Trials

An automatic reminder supported by low-burden facilitation increased delivery of a universal secure firearm storage program during pediatric primary care.

A new study, funded in part by the National Institute of Mental Health, showed that a new medication derived from ketamine is safe and acceptable for use in humans, setting the stage for clinical trials testing it for hard-to-treat mental disorders like severe depression.

In an NIMH-funded study, a comprehensive collaborative care intervention significantly reduced post-traumatic stress disorder (PTSD) symptoms among trauma patients from racial and ethnic minority backgrounds.

NIMH-supported research captures expressions of irritability across developmental stages via a clinically relevant measurement tool: the MAPS Temper Loss Scale.

A new study by NIMH researchers demonstrated the effectiveness, feasibility, and safety of exposure-based cognitive behavioral therapy for severe irritability and temper outbursts in children. The positive results set the foundation to continue exploring exposure therapy as a potential treatment for childhood irritability.

Results from a large clinical trial funded by the National Institutes of Health show that an intervention for anxiety provided to pregnant women living in Pakistan significantly reduced the likelihood of the women developing moderate-to-severe anxiety, depression, or both six weeks after birth.

This clinical trial found that MST is equally effective at reducing depression symptoms as ECT, but with fewer side effects.

Evidence-based practices for suicide prevention effectively reduced suicidal behaviors among adults seen for care in emergency departments.

An NIMH-supported study suggests that a brief self-association training program can extend the effects of a single ketamine infusion by shifting people’s negative self-beliefs.

The NIMH Healthy Research Volunteer Study aims to build a comprehensive, publicly accessible resource with a range of brain and behavioral data from healthy volunteers.

TMS can only directly stimulate the outermost layer of the brain, but NIMH researchers have found that mapping a person’s brain architecture may make it possible to guide TMS to deep brain targets.

A new study shows the use of a clinical decision support system to prompt the use of shared decision-making tools, such as handouts, may result in positive impacts on long-term cardiovascular health in patients with serious mental illness.

An analysis of clinical trial data shows that improvements in emotion regulation in youth at high risk for suicide who received dialectical behavior therapy (DBT) led to a reduction in self-harm behaviors.

NIMH is working to meet the urgent need for rapid-acting suicide prevention interventions by supporting research investigating the feasibility and safety of treatment protocols that have the potential to quickly reduce severe suicide risk in youth and adults.

In a project funded by the NIMH Small Business Technology Transfer program, researchers are investigating whether mobile technology can be used to create a passive monitoring system that can predict teens’ depressive symptoms and improve the quality of their care.

Carlos Zarate Jr., M.D., chief of the Experimental Therapeutics and Pathophysiology Branch within the NIMH Intramural Research Program, has been elected to the National Academy of Medicine.

Experts from the National Institute of Mental Health are available to speak on topics related to suicide and suicide prevention, including the warning signs of suicide, suicide prevention methods, trends in suicide rates, how to find mental health help and support, and the latest in suicide prevention research.

In a new paper, published in JAMA Psychiatry, NIMH looks forward, outlining the next stages in the Institute’s suicide prevention research priorities.

An innovative NIMH-funded trial shows that a receptor involved in the brain’s reward system may be a viable target for treating anhedonia (or lack of pleasure), a key symptom of several mood and anxiety disorders.

The use of right unilateral ultrabrief pulse (RUL-UB) electroconvulsive therapy (ECT) in combination with the antidepressant venlafaxine to treat depression in elderly patients is well tolerated and results in minimal neurocognitive side effects, according to a new NIH-funded study published in the American Journal of Geriatric Psychiatry.

In 2018, 11.4 million adults in the United States experienced a serious mental illness, such as schizophrenia-spectrum disorders, severe bipolar disorder, and severe depression.

NIH-funded research uses machine learning algorithm to predict individual response to a commonly-prescribed antidepressant.

Researchers have uncovered sex-based differences in the development of the hippocampus and amygdala—brain areas that have been implicated in the biology of several mental disorders that impact males and females differently.

NIMH awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis.

Mental health research center directors emerged from a recent meeting with a renewed commitment to help each other achieve their common mission – to transform care of children, adolescents and adults with severe psychiatric disorders.

FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.

A research team found nearly one-third of youth ages 10 to 12 years screened positive for suicide risk in emergency department settings, including those seeking help for physical concerns only.

NIMH-funded scientists have discovered a pattern in the way a brain circuit works that may help predict the onset of psychosis. High levels of chatter, or “hyperconnectivity,” in a circuit involving the cerebellum, thalamus, and cortex emerged as a potential “neural signature” in a functional magnetic resonance imaging (fMRI) study.

Findings from a new study suggest an electronically delivered HIV prevention intervention may be effective in reducing sexually transmitted infections (STIs) and sexual risk behaviors in young men who have sex with men.

A recent clinical trial of a psychotherapy called dialectical behavior therapy (DBT)—which has been shown to be effective in reducing suicide-related behavior in adults—showed that DBT can also reduce suicide attempts and suicidal behavior in adolescents.

Researchers funded by the National Institutes of Health have shown that a therapy-based treatment for disruptive behavioral disorders can be adapted and used as an effective treatment option for early childhood depression.

The National Institutes of Health released to the scientific community an unparalleled dataset from the Adolescent Brain Cognitive Development (ABCD) study.

Two standard medications for bipolar disorder were effective in controlling symptoms at doses tailored to older people in a clinical trial of treatment in adults over age 60.

Functional connectivity magnetic resonance imaging (fcMRI) may predict which high-risk, 6-month old infants will develop autism spectrum disorder (ASD) by age 2 years.

A streamlined behavioral therapy delivered in a pediatrics practice offered much greater benefit to youth with anxiety and depression than a more standard referral to mental health care with follow-up in a clinical trial comparing the two approaches.

The study will follow the biological and behavioral development of more than 10,000 children through adolescence into early adulthood.

An individualized program of follow-up treatment with electroconvulsive therapy (ECT) combined with an antidepressant was effective in preventing relapse in patients 60 years and older who had had a successful initial course of treatment for severe depression.

Is mobile mental health research the next frontier for smartphones? Based on Dr. Patricia Areán’s pioneering BRIGHTEN study, research via smartphone app is already a reality.

Coordinated Specialty Care for First Episode Psychosis is Cost Effective

Two of the world’s largest brain tissue banks unify efforts to collect and distribute a critical number of brain donations for important autism research.

New research shows that a team-based, coordinated specialty care treatment plan produces better outcomes than typical community care for people with first episode psychosis. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.

James McPartland, Ph.D. of Yale University will lead a new four-year $28 million Biomarkers Consortium project that aims to improve clinical evaluation of treatments for social impairment in children with autism.

NIMH’s first major effort to share clinical trial research data—established before many current data registries existed—is still doing a brisk business.

NIMH Twitter Chat on Men and Depression

Many patients with first-episode psychosis receive medications that do not meet guidelines. A study finds that almost 40 % of people with first-episode psychosis in community mental health clinics across the country might benefit from medication treatment changes.

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

A groundbreaking study will help researchers learn more about treating people with suicidal thoughts. Nearly 20,000 patients will be able to enroll in the trial. One of the treatments being tested was developed with the help of other patients

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

Treatment adherence is a problem among people with schizophrenia, who may not take medications because they don’t perceive its need or benefit, don’t like the side effects, or forget. To combat this issue, long-acting injectable medications are administered every 2-4 weeks. But are the new forms of these drugs better than the old ones?